Mab-80R-ScFv-IgG-CH3 – 1.0 mg

85,00 excl. Vat

Categories: ,

X-MAB-0008 – Mab-80R-ScFv-IgG-CH3
PRODUCT CODE: X-MAB-0008-1.0MG
ALIQUOTING: 1 X 1.0 mg vial
STORAGE: < -18 °C

PRODUCT DESCRIPTION
The original 80R antibody was identified as a potent neutralizing human monoclonal antibody against the SARS-COV-1 Spike-S1 RBD that blocks the binding of S1 to ACE2, prevents the formation of syncytia in vitro and inhibits viral replication in vivo. Recombinant Mab-80R-ScFv-IgG antibody is a ScFv-human-IgG-CH3 domain recombinant modubody version of 80R for research use only. 80R as pure ScFv and biotinylated ScFv antibody fragment. For convenient amino-based conjugation, the product is free from amino-based puffers.

PRECAUTIONS AND DISCLAIMER
This product is for LABORATORY RESEARCH USE ONLY, not for diagnostic, therapeutic, drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.


FORMULATION
For shipping at ambient temperature the protein is liquid-stabilized with a HEPES, NaCl, small molecule buffer base at neutral pH.


PREPARATION AND HANDLING
Stock solutions can be diluted in appropriate buffers.

STORAGE / STABILITY
For long term storage the liquid-stabilized protein should be stored below – 18 °C. Repeated freeze-thaw cycles (> 5) should be avoided. For long term usage, stock solutions can be frozen in working aliquots.


CHARACTERISTICS
The E. coli expressed recombinant 80R-ScFv- IgG-CH3 has a molecular mass of 43 kDa and a predicted isoelectric point of 8.8.


RECOMMENDED DILUTION
For protein conjugation a final concentration of 0.2 to 1 mg/ml is recommended. For direct microplate coating a final concentration of 0.5 to 5 μg/ml is recommended. For optimal performance the reagent should be titrated for each application.


BACKGROUND REFERENCES
1. Yuan M. et al., A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV, Science. 368: 630- 633 (2020).

2. Meulen J., et al. Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants, PlosMed. https://doi.org/10.1371/ journal.pmed.0030237, (2006).

 

BioThinx warrants, that at the time of the quality release or subsequent retest date this product conformed to the information contained in this publication. Purchaser must determine the suitability of the product(s) for its particular use. Additional terms and conditions may apply. Please see reverse side of the invoice or packing slip. No other warranties, express or implied, are granted, including without limitation, implied warranties of merchantability, fitness for any particular purpose, or non-infringement